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BRIEF REPORT
Can intravenous oxytocin infusion counteract hyperinflammation in
COVID-19 infected patients?
Benjamin Buemanna , Donatella Marazzitib and Kerstin Uvn€as-Mobergc
aVeksø, Denmark; bDepartment of Experimental and Clinical Medicine, Section of Psychiatry, University of Pisa, Pisa, Italy;
cDepartment of Animal Environment and Health, Swedish University of Agricultural Sciences, Skara, Sweden
ABSTRACT
Objectives: Based on its well-documented anti-inflammatory and restorative properties we pro-
pose trials with the natural hormone oxytocin for treatment of hospitalised Covid-19 patients.
Methods: We searched for, retrieved, and commented on specific literature regarding multiple
functions of oxytocin with a special focus on its modulation of inflammatory, immune, and
restorative functions.
Results: Available data gathered in animals and humans support the anti-inflammatory proper-
ties of oxytocin. The multiple anti-inflammatory effects of oxytocin have been demonstrated
in vitro and in vivo in various animal models and also in humans in response to intravenous
infusion of oxytocin. Furthermore, oxytocin has been documented to activate several types of
protective and restorative mechanisms and to exert positive effects on the immune system.
Conclusions: In addition, to being anti-inflammatory, it may be hypothesised, that oxytocin may
be less suppressive on adaptive immune systems, as compared with glucocorticoids. Finally, by
its restorative effects coupled with its anti-stress and healing properties, oxytocin may shorten
the recovery period of the Covid-19 patients.
ARTICLE HISTORY
Received 16 April 2020
Revised 2 August 2020







The world is presently experiencing an unprecedented
pandemic outbreak with a new coronavirus, the SARS-
CoV-2, giving rise to the Covid-19 disease. Presently,
the incidence of the disease is stable in most
European countries, but the pandemic appears to
remain in a progressive phase in United States, South
America, India and some third world countries. Not
only is the virus highly infective, but also the mortality
of the disease is not negligible, particularly in elderly
people and individuals with a generally poor health
status. The fatal cases are frequently linked to an
exaggerated inflammatory reaction to the virus. In the
most severe cases, the patients develop acute respira-
tory distress syndrome (ARDS) characterised by
impaired respiration due to lung edoema and alveolar
collapse. Hyperinflammation is an important factor in
the pathogenesis of ARDS where the inflammation
may progress towards a systemic cytokine storm that
may cause multiorgan failure (Zhang et al. 2020).
Apart from the hyperinflammation the cellular
immune system may be severely affected in the
advanced stages of the disease with low T-cell and
NK-cell counts. Different types of anti-inflammatory
drugs have been introduced in the treatment of critic-
ally ill Covid-19 patients to counteract the inflamma-
tory damages of both the organs and the immune
system (Zhang et al. 2020). However, such an
approach is always a delicate matter as it may further
weaken the capability of an already impaired immune
system to fight the disease.
More recent data show that prior to the develop-
ment of ARDS, many patients display hypoxia which
may be due to a dysfunctional pulmonary perfusion
pattern caused by a disrupted endothelial function
(Gattinoni et al. 2020). Hyper-perfusion of hypoxic
areas of the lungs may lead to an impaired oxygen-
ation of the blood despite a relatively well-preserved
ventilatory capacity. Severe cases of hypoxaemia
which may appear at relatively early stages of the
Covid-19 disease constitute a bad prognosis, as a
blood oxygen saturation <90% is a strong predictor of
mortality (Xie et al. 2020). In such cases, aggressive
therapy including respiratory aid is mandatory.
In this urgent situation, immediately available and
safe substances with a high potential to antagonise
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inflammation and to restore the endothelial function
are called for. Oxytocin is a hormone which promotes
uterine contractions during birth but is also involved
in the regulation of social behaviour and stress reac-
tions. However, more recently oxytocin has been rec-
ognised also to play an important role in the
modulation of inflammatory responses and the stimu-
lation of multiple tissue protecting and restorative
mechanisms (Buemann and Uvn€as-Moberg 2020).
The use of oxytocin for the treatment of Covid-19
has recently been proposed in a short communication
referring to its different protective and anti-inflamma-
tory effects (Soumier and Sirigu 2020). Furthermore, a
positive impact of oxytocin against Covid-19 has been
suggested based on the clinical observation that mor-
bidity and mortality of the Covid-19 infection appear
to be more pronounced in groups of individuals
known to have low levels of oxytocin, and thereby
supposedly a low function of oxytocin (Diep et al.
2020). In the present paper, we further argue for a
potential of oxytocin to alleviate the course of a SARS-
CoV-2 infection by referring to several protective
effects of oxytocin demonstrated in vitro and in animal
and human studies.
In clinical practice oxytocin infusion is widely used
to promote uterine contractions during labour and to
inhibit postpartum bleedings (Uvn€as-Moberg et al.
2019). Both the pharmacokinetics of oxytocin as well
as its safety profile are well described (Nielsen et al.
2017). Intravenous (i.v.) infusion of oxytocin has also
been tested in human experiments within various con-
texts including expressions of inflammation in a study
performed on healthy men (Table 1).
In the present work we further investigated the
possible potential of oxytocin to mitigate the course
of SARS-CoV-2 infection. As part of our literature
retrieval we performed a search in PubMed applying
the search profile:
(Oxytocin[Title]) AND ((inflammation[Title/Abstract]) OR
(inflammatory[Title/Abstract]) OR (macrophage[Title/
Abstract]) OR (immune[Title/Abstract]) OR
(lymphocyte[Title/Abstract]) OR (covid[Title/Abstract])
OR (injury[Title/Abstract]) OR (damage[Title/Abstract])
OR (endothelial[Title/Abstract]) OR (endothelium[Title/
Abstract]) OR (cytokine[Title/Abstract]) OR (PPAR[Title/
Abstract]) OR (TNF[Title/Abstract]) OR
(protective[Title/Abstract])).
In this search, we retrieved 468 articles of which 35
are cited in the present paper. The remaining were
excluded as review articles or having a focus on
behaviour, pain, atherosclerosis, diabetes, energy bal-
ance or reproduction.
Anti-inflammatory effects of oxytocin
Numerous in vitro and in vivo animal studies docu-
mented a capacity of oxytocin to exert anti-inflamma-
tory and anti-oxidative effects by a plethora of
pathways summarised in Box 1 involving direct recep-
tor mediated mechanisms (Tables 2 and 3).
Furthermore, observations in rats of an increased
plasma oxytocin level during early stages of sepsis
may point to a down-regulatory role of oxytocin on
e.g. the innate (unspecific) immune system (Oliveira-
Pelegrin et al. 2013).
Table 1. Human studies using i.v. infusion.
Reference Study group Administration
Achieved max plasma
concentration Assessed outcome
Clodi et al. (2008) 10 healthy younger men 600 mIU/kg/min over
90min. 5,4 mg in total
at 60kg
170 pg/ml 
approx. 4x basal level
Attenuated response of diff.
inflammatory cytokines and
body temp. to bacterial toxin.
Nielsen et al. (2017) 33 healthy
postmenopausal women
Single dose of oxytocin,
10 IU  16,7 mg or






Burt et al. (1963) 20 healthy post-
labour women.
Single dose of oxytocin,
10 IU  16,7 mg per kg
body weight
not reported Plasma: NEFA ", glucose #
Hollander et al. (2003) 14 male þ 1 female with
autism
spectrum disorders.
14 IU in total during 4h
incremental protocol
Not reported Behavioral parameters
Increased social competence
Legros et al. (1984) 6 younger men 0,016 lU/min over 30min 
0,8 mg in total
29,5 pg/ml Plasma ACTH #, cortisol #
Page et al. (1990) 6 lean younger men 0,111 IU/min over 4h 
44,5 mg in total
133,6 pg/ml Ablated response of ACTH to CRH.
Other adenohypophysal
hormones unaffected
Ohlsson et al. (2004) 14 healthy women 20–40 mIU/min over 90min

3–6 mg in total.
not roproted Colonic antegrade peristaltic
contractions "
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Table 2. Animal studies on the anti-inflammatory, antioxidative and restorative effects of oxytocin.
Reference
Study
group Stimulation Oxytocin manipulation Organ Assessed outcome









TNF-a plasma levels #
Glutathione "
Collagen levels in organs #
_Işeri et al. (2005b) Rats Acetic acid in colon 0.5mg/kg 2x daily for
4 days.









Rats Ischaemia/reperfusion 25 ng/kg/h
subcutaneously
for 3 or 7 days
Heart Neutrophil infiltration #
TNF-a and IL-6 #
Necrosis, apoptosis and fibrosis #
Proliferating cell nuclear antigen
(PCNA) "
Post-infarction contractability "









Petersson et al. (2001) Rats Carrageenan injection One dose 100 mg/kg
subcutaneously









Whole body Serum IL-1b, IL-6 and TNF-a #
Particular TNF-a went down to a
level comparable to that of
the young.
Rashed et al. (2011) Rats Cisplatin injected
intraperitoneally
Single dose of 1mg/kg
intraperitoneally.
Kidney Gene expression of NADPH oxidase
and P38 MAPK #
GSH and SOD "
Histology normalised










Obese mice None 50 mg/day
subcutaneously
daily for 2 weeks
Adipose tissue TNF-a #




Lung Pro-inflammatory cytokine and NF-jB
gene expression in lung tissue #
Index of edoema #
Pathological injury #
Myeloperoxidase as a marker of
neutrophil infiltration #
Lin et al. (2019) Rats Heat stress 5-80 lg/kg
intravenously




Markers of oxidative stress #
Time of survival "









daily for 2 weeks.
Intestine Protection of mucosal structure (villi
and crypts) and primordial cells
with both treatments.












Rats Ischaemia/reperfusion 0.0001, 0.001, 0.01, 0.1
or 1 mg
intraperitoneally.
Heart Infarct size #
Plasma levels of creatine kinase-MB
isoenzyme (CK-MB) and lactate
dehydrogenase (LDH) #
Greatest effect at 0.1 mg.
Senturk et al. (2013) Rats Ischaemia/reperfusion 0.5 lg/kg
intraperitoneally
Bladder Tissue malondialdehyde (Lipid
peroxidation) #
GSH "
Mast cell count in mucosa #
Improved histopathology
(continued)




group Stimulation Oxytocin manipulation Organ Assessed outcome
Stadnikov et al. (2011) Albino rats Intratracheal injection






daily for 7 days
Lung Number of apoptotic cells #
Bcl-2, clara cell protein (CC-16) "










Akdemir et al. (2014) Rats Ischaemia/reperfusion 80 IU/kg
intramuscularly
Ovaria Tissue malondialdehyde (Lipid
peroxidation) #
Edoema and follicular degeneration #
Erkanli et al. (2013) Rats Ischaemia/reperfusion 0.5ml/kg
intraperitoneally
Skeletal muscle Tissue malondialdehyde (Lipid
peroxidation) #









Liver Tissue malondialdehyde (Lipid
peroxidation) #
Improved histopathology




daily for 5 days
Heart Infarct size after 14 days #
Myocardial activation of prosurvival
signals (phosphorylation of STAT3,
ERK, eNOS) after 2 days "
Expression of the anti-apoptopic and
anti-necrotic factor Bcl-2"
Expression of angiogenetic factors
VEGF "
Expression of the antifibrotic factor
MMP "









Number of apoptotic cells #
Infarct size #
Lactate dehydrogenase activity #
Arrhythmias #
Karelina et al. (2011) Mice Ischaemia/reperfusion 20 ng intracerebro-
ventricular daily for
3 days
Brain Cerebral IL6 "
Infarct size after 3 days #
Zhang et al. (2007) Rats Ischaemia/reperfusion 20, or 100 lg
intraperitoneally
Stomach Mucosal damage #
Gastric pH "
Gastric fluid output #





Nerve function EMG deteriorations #
TNF-a plasma levels #
Plasma malondialdehyde (Lipid
peroxidation) #





Stomach and skin Damage on skin and gastric mucosa #




Vitalo et al. (2009) Rats Skin burns 10mg/kg
intraperitoneally
Skin (inflicted wounds) Improved healing
Xiong et al. (2020) Rats Ischaemia/reperfusion 0.1 lg/kg,
intraperitoneally
prior to I/R
Heart Infarction size #
Arrhythmias #
Improved hemodynamics
Mast cell degranulation #
Yuan et al. (2016) Mice LPS injected
intraperitoneally
Nasal administration Brain Inflammatory morphology changes of
microglia cells in prefrontal cortex
#
Protein and gene expression in
prefrontal cortex of TNF-a, IL-1b,
iNOS and COX-2#
Sorg et al. (2017) Mice Dorsal surgical wound 1mg/kg or 10mg/kg
intraperitoneally
Skin (inflicted wounds) No effects of oxytocin on
healing processes







Kidney Improved glomerular and tubular
histopathology.
Tissue TGF- b and CRP #
(continued)
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Patients with severe Covid-19 are characterised by
an elevated neutrophil-to-lymphocyte ratio compared
to those being less affected (Lagunas-Rangel FA 2020)
indicating that hyperactivity of these most abundant
leucocyte plays a pivotal role in the severe pathogen-
esis of the disease. Autopsies from patients who
had died from a Covid-19 infection demonstrate
extensive neutrophil infiltration in pulmonary capilla-
ries accompanied by fibrin deposition. Furthermore,
aberrant neutrophil activity could in part explain the
micro-thrombotic condition in Covid-19 patients
(Barnes et al. 2020).
Oxytocin has been shown to dampen the inflamma-
tory response of neutrophils in multiple animal mod-
els. Multi-organ damages caused by sepsis have been
reported to be ameliorated by oxytocin in rats
together with decreased tissue inflammatory cell infil-
trations (Işeri et al. 2005a). At the same time, the neu-
trophil response in the different tissues assessed by
myeloperoxidase activity was blunted. Oxytocin has
also been reported to reduce the neutrophil response
to acetic acid infused in the colon and to renal E coli
infection, which was accompanied by an amelioration




group Stimulation Oxytocin manipulation Organ Assessed outcome
Erbas et al. 2017 Rats Diabetes induced by
single dose of
streptozotocin
80 lg/kg or 160 lg/
kg intraperitoneally
for 4 weeks
Nerve function EMG deteriorations #
Muscle strength " with high dose.




Table 3. In vitro and in situ studies on the anti-inflammatory and antioxidative effects of oxytocin.
Reference Organ, tissue, cells Stimulation Oxytocin administration Assessed outcome
Oliveira-Pelegrin et al. (2013) Rat peritoneal
macrophage culture
In vivo: Caecal ligation
puncture induced sepsis
followed by In vitro LPS-
stimulation.
1 or 100 pM in medium Production of nitrite, TNF-a
and IL-1 #




IL-1ß in the pouch #
Deing et al. (2013) Cultured human fibroblasts
and keratinocytes




and IL 6, CCL5 and
CXCLlO release "




TNFa to endothelial cells
10 or 100 pM to medium NADPH superoxide
production #
IL-6 secretion #
Szeto et al. (2017) Cultured human
macrophages
LPS added to the medium 100 pM to medium IL-6 secretion #
Garrido-Urbani et al. (2018) Cultured mouse
macrophages
None ? M1/M2 ratio #
TNF-a #




10 nM to medium Senescent phenotype
acquiring #
Karelina et al. (2011) Cultured microglia from
mouse brain
LPS added to the medium 0.1 or 1 lM to medium MHC class II expression as
measure of microglial
reactivity #
Ross et al. (2013) Cultured human monocytes
and macrophages
LPS added to the medium 10–1000 pM to medium Absent effect of oxytocin
on inflammatory
cytokine response
Clodi et al. (2008) Isolated human peripheral
blood mononuclear cells
LPS added to the medium 10 pM–10 nM to medium Absent effect of oxytocin
on TNF-a and IL-
6 responses
Inoue et al. (2019) Cultured mouse
microglia cells
LPS added to the medium 1 mM to medium TNF-a #
IL-6 and TNF-a gene
expression #
Yuan et al. 2016 Cultured mouse
microglia cells
LPS added to the medium 1 mM to medium Protein and gene
expression of TNF-a, IL-
1b, iNOS and COX-2#
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reduced oxidative stress and an attenuated response
of pro-inflammatory cytokines (Işeri et al. 2005b, Biyikli
et al. 2006). A reduced neutrophil response with less
tissue damages as a result of oxytocin treatment has
also been found in rats with ischaemia–reperfusion
experiments of the liver (D€uş€unceli et al. 2008) and
kidney (Tugtepe H 2007) as well as myocardial infarc-
tion (Jankowski M 2010). Furthermore, less neutrophil
activity was seen in the hind paw where inflammation
was introduced by injection of carrageenan if oxytocin
had been given subcutaneously (Petersson et al.
2001). In that study, the attenuating effect on the
edoema by oxytocin administered in moderate doses
was comparable to what could be achieved by dexa-
methasone. The dampening effect by oxytocin on the
neutrophil activity may involve a downregulation of
the toll-like receptor-4 (Mou et al. 2020) which is
essential for the capacity of these cells to infiltrate tis-
sues, as demonstrated in lung tissue (Hu et al. 2010).
In macrophages, oxytocin may attenuate their tran-
sition into a pro-inflammatory phenotype by upregula-
tion of b-arrestin 2 (Tang et al. 2019). This is
associated with an inhibition of nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-jB)
signalling, as demonstrated in lipopolysaccharide
stimulated macrophages (Tang et al. 2019). NF-jB is a
prominent transcription factor for a pro-inflammatory
immune response including production of pro-inflam-
matory interleukins and TNF-a. When NF-jB is
antagonised, it may therefore result in a decreased
release of TNF-a from different cell types as observed
with oxytocin treatment in a study on mice (Garrido-
Urbani et al. 2018). A pivotal role of oxytocin as a
modulator of the innate immune response is further
supported by findings that the oxytocin receptor gene
is increased 10-fold when monocytes differentiate into
macrophages (Szeto et al. 2008). Interestingly, oxytocin
may, by exerting such an inhibitory effect on inflam-
matory activity, have the capacity to be part of a
negative cellular feed-back mechanism on inflamma-
tory responses. This is supported by observations
showing that the expression of the oxytocin receptor
gene in human macrophages is upregulated during
inflammation by a NF-jB dependent mechanism
(Szeto et al. 2017).
Some in vitro studies on isolated monocytes and
macrophages did not find an attenuated pro-inflam-
matory cytokine response to bacterial lipopolysacchar-
ide endotoxin (LPS) when preincubated with oxytocin
(Clodi et al. 2008, Ross et al. 2013). The diminished
innate immune response to different immune chal-
lenges associated with oxytocin treatment on organ
and whole-body level (Tables 1 and 2) may therefore
depend on effects on other immune cells e.g. neutro-
phils, or involve central mechanisms.
The dampening impact of oxytocin on the inflam-
matory activity of different immune cells may involve
an upregulation of peroxisome proliferator-activated
receptor gamma (PPAR-!). PPAR-! is an important
transcription factor inhibiting the inflammatory
response and is therefore a target for several anti-
inflammatory drugs. PPAR-! receptor agonists are also
used to attenuate the inflammatory activity during
viral lung infections, however, PPAR-! may be down-
regulated in alveolar macrophages by viral lung infec-
tions (Huang et al. 2019). In rat adipose tissue, PPAR-!
gene expression has been found to be upregulated
after two weeks of oxytocin treatment (Eckertova et al.
2011). If oxytocin also upregulates PPAR-! in some
types of immune cells in the lungs it might reinforce
the effects of anti-inflammatory treatment with PPAR-
! receptor agonists.
The anti-inflammatory effect of oxytocin may also
involve a suppression of the gene expression of nico-
tinamide adenine dinucleotide phosphate (NADPH)
oxidase. This enzyme is responsible for the inflamma-
tion induced superoxide production and thereby the
formation of Reactive Oxygen Species (ROS). Such an
effect of oxytocin was demonstrated in kidney hom-
ogenate from rats being treated with intraperitoneal
injection of cisplatin (Rashed et al. 2011). In the same
study, the gene expression of p38 mitogen-activated
protein kinase (MAPK), an enzyme involved in the
apoptotic pathway, was also reduced by oxytocin. The
latter effect may protect the tissue against further
destruction. These observations are in line with find-
ings of a decreased basal and stimulated NADPH-
dependent superoxide activity in human vascular cells,
monocytes, and macrophages when the cells were
Box 1. Summarised probable anti-inflammatory mechanism
of oxytocin.
 NADPH oxidase expression # ! ROS production #
 NF-jB signaling # ! Number of macrophages with a pro-
inflammatory phenotype # ! production of pro-inflamma-
tory cytokines including TNFa #
 PPAR-! receptor expression " ! sensitivity to anti-inflamma-
tory PPAR-!-agonists "
 Parasympathetic activity " ! cholinergic stimulation of
immune cells "
 Stimulation of mesenchymal stem cells ! tissue anti-inflam-
matory mechanisms "
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incubated with oxytocin at physiological levels (Szeto
et al. 2008).
Does oxytocin counteract ARDS-development by
defending endothelial integrity? Endothelial cells
achieved from different kinds of blood vessels includ-
ing pulmonary arteries express oxytocin receptors and
produce nitric oxide (NO) when stimulated by oxytocin
(Thibonnier et al. 1999). This release of NO by oxytocin
is a result of the stimulation of endothelial nitric oxide
synthase (eNOS) probably partly mediated by the pro-
tein kinase B (Akt)-pathway (Gonzalez-Reyes et al.
2015). An increased endothelial NO production may
counteract the adherence of neutrophils to the endo-
thelium and formation of platelet-neutrophil aggre-
gates in a state of hyperinflammation (Khan et al.
2010). The anti-inflammatory adipokine omentin acting
similarly to oxytocin in this regard has been demon-
strated to protect the endothelial barrier in the lungs
in mice with LPS-induced ARDS where the develop-
ment of edoema was counteracted (Qi et al. 2016).
The claim that NO is involved in pulmonary vascular
protection during lung inflammations is supported by
a decrease of pulmonary edoema in a study where
rats were treated with adipose tissue derived stem
cells after an acute lung injury was introduced by LPS
(Gao et al. 2013). This effect was accompanied by an
increased eNOS expression. A protective NO mediated
effect of oxytocin on the vascular endothelium in the
lungs may therefore be hypothesised.
Furthermore, the Covid-19 patients show signs of a
damaged endothelial function caused by a disruption
of the angiotensin system. This may be a result of the
virus binding to the ACE-2 receptor causing elevations
of angiotensin 2, which in turn, leads to vascular
inflammation and an increased coagulation activity
(Leisman et al. 2020). In this situation, a protective
effect by oxytocin on the vascular endothelium in the
lungs may be very beneficial. This may also apply to
the inhibition of platelet aggregation by endothelium-
derived NO.
Oxytocin may potentiate the adaptive
immune response
In addition to exerting anti-inflammatory and restora-
tive effects, oxytocin may also support the adaptive
immune system by stimulating cellular maturation and
differentiation of lymphocytes. In this regard, oxytocin
may act on receptors on different types of T lympho-
cytes and support their differentiation and survival
(Hansenne et al. 2005). Moreover, oxytocin may
potentiate the adaptive immune response by
enhancing the proliferation of lymphocytes when they
are exposed to antigens (Maccio et al. 2010).
Furthermore, oxytocin may protect lymphocytes dur-
ing oxidative stress combined with hypercortisolemia
(Stanic et al. 2016). Taking these protective and stimu-
latory effects on the immune system into account,
oxytocin differs from many other types of anti-inflam-
matory treatments by at the same time being anti-
inflammatory and exerting some positive effects on
the adaptive immune response.
Protective and restorative effects of oxytocin
Oxytocin has been reported to mitigate tissue dam-
ages in different inflicted injury models. This includes
sepsis (Işeri et al. 2005a) and global thermal trauma in
rats (Işeri et al. 2008) and different local intestinal
injury models in mice (Chen et al. 2015). Moreover,
oxytocin has been shown to reduce sepsis induced
polyneuropathy in rats (Erbaş et al. 2013). Pertaining
particularly to inflammation in the lungs, oxytocin has
recently been reported to reduce the severity of bac-
terial LPS-induced acute lung injury in mice showing
less damages and edoema of the tissue (An et al.
2019). Furthermore, the treatment with oxytocin atte-
nuated the responses to LPS regarding gene expres-
sion and appearance of pro-inflammatory cytokines in
the lungs. Accordingly, the elevation in the expression
of NF-jB was ablated. Oxytocin has also been demon-
strated to alleviate the consequences of a heat stroke
elicited acute lung injury in rats (Lin et al. 2019). A
blunted inflammatory response was also seen in this
case together with an improved survival.
Reduced tissue damages associated with lung infec-
tions imposed by E. coli bacteria have been demon-
strated. In one study, stressed rats were given a lung
infection by intratracheal injection of an E. coli suspen-
sion (Stadnikov et al. 2011). In that study, intra-muscu-
lar injections of oxytocin resulted in a reduction of the
apoptotic cells in the lungs after 11 days. In another
study, E. coli bacteria were injected into the renal
medulla and the animals were examined after one or
7 days (Biyikli et al. 2006). In this case, the elevations
of oxidative stress markers in the tissue observed after
7 days was antagonised by oxytocin as was the
response in plasma TNF-a.
It is not an uncommon phenomenon that the myo-
cardium is affected by Covid-19, which may lead to a
fatal outcome particularly in patients, who suffer from
heart comorbidities (Kochi et al. 2020). Oxytocin has
been demonstrated to possess potent cardioprotective
properties in different models. Thus, in situ ischaemia/
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reperfusion and infarct experiments with isolated
hearts have shown an improved resilience to transient
hypoxia of the myocardium with less injuries following
administration of oxytocin (Houshmand et al. 2009,
Xiong et al. 2020, Jankowski et al. 2010). As inflamma-
tory reactions are involved in the organ damages
attributable to hypoxaemia (Wei et al. 2016), the anti-
inflammatory impact of oxytocin may play a protective
role in such conditions being accompanied by an
increased activation of anti-apoptotic and restorative
pathways (Kobayashi et al. 2009, Polshekan et al.
2019). Moreover, a protective effect of oxytocin
against damages caused by transient hypoxia has
been confirmed in a number of ischaemia/reperfusion
experiment in a variety of other organs (Table 2)
including a study where damages inflicted on the liver
by ischaemia/reperfusion of the kidney was alleviated
by oxytocin (Hekimoglu et al. 2013) indicating this
mechanism also may act on a systemic level.
The tissue protective role of oxytocin may not be
limited to anti-inflammatory and anti-apoptotic mech-
anisms; more direct healing and regenerative effects
on tissues may also be exerted by oxytocin. The cap-
acity of oxytocin to promote the function of stem cells
(Noiseux et al. 2012) may be part of the restorative
function of oxytocin. In this context the capacity of
mesenchymal stem cells to repair ischaemic heart
damage in rats has been reported to be enhanced
after preconditioning with oxytocin (Kim et al. 2012).
Stem cells may also contribute to the cardio-protective
effect of oxytocin as demonstrated in diabetic rats
(Plante et al. 2015). A general stimulatory effect of
oxytocin on stem cells might also be of significance in
the alveolar tissue as such cells may promote restor-
ation, in addition to attenuating pulmonary inflamma-
tion (Mei et al. 2010). An over-all restorative potential
of oxytocin is also demonstrated by experiments in
rats showing increased rate of mitosis and an
improved rate of wound healing following administra-
tion of oxytocin (Vitalo et al. 2009, Petersson et al.
1998, Xu et al. 2017). Concordantly, wound healing
was accelerated in mice receiving an oxytocin promot-
ing probiont, which stimulates the release of oxytocin,
an effect which was absent in oxytocin gene knock-
out mice (Poutahidis et al. 2013). Oxytocin has also
been found to restore striated muscles and therefore
counteract sarcopenia in rats (Elabd et al. 2014). These
observations suggest a global restoring potential of
oxytocin that may involve most types of tissues.
Oxytocin might therefore be applied to improve the
chance for a general successful recovery of damaged
organs in the severely affected Covid-19 patient.
Human studies
Oxytocin has also in humans been shown to exert
anti-inflammatory, antioxidant and restorative effects.
Intravenous infusion of oxytocin (1 ng/kg/min for
90min) was reported to blunt the febrile response
and the response of several proinflammatory cyto-
kines, including that of TNF-a, caused by a bolus injec-
tion of LPS in healthy men (Clodi et al. 2008). In
another study an anti-inflammatory effect of oxytocin
was demonstrated in human skin, as knockdown of
the oxytocin receptor (OXTR) in cultured skin cells was
found to increase levels of reactive oxygen species
(ROS) and reduce the level of glutathione (GSH).
Moreover, the OXTR-depleted keratinocytes exhibited
an increased release of the pro-inflammatory cytokines
IL6, CCL5 and CXCL10 (Deing et al. 2013). Local intra-
vaginal application of oxytocin for one week rejuven-
ated the vaginal mucosa by increasing the number of
cell layers and the maturation of the cells (Jonasson
et al. 2011) (Al-Saqi et al. 2015). Together these data
indicate that oxytocin also in humans can exert anti-
inflammatory, antioxidant and restorative effects.
Clinical considerations
Based on the in vitro mechanistic experiments and the
in vivo animal and human studies presented above
we find it conceivable that administration of oxytocin
could be helpful in the treatment of Covid-19 and
should be tested in clinical trials.
In connection with birth, oxytocin is given in doses
from 1–32 mIU/min over several hours. After birth
often 5 or 10 IU are given as a bolus to prevent bleed-
ings. Side effects are rare, but water intoxication has
been shown to occur in response to infusion of
extremely high doses of oxytocin. Bolus administration
of 10 IU has been observed to influence heart rate and
blood pressure in rare cases (Uvn€as-Moberg
et al. 2019).
The pharmacokinetics of oxytocin are well studied,
and the half-life is around 30minutes (Nielsen et al.
2017). Oxytocin levels increase by 1-2 pg/ml in
response to an increased rate of infusion by 1 mIU/
min and when the rate of oxytocin infusion is
doubled, the oxytocin level in the circulation is also
doubled both in women during labour and in healthy
males (Uvn€as-Moberg et al. 2019, Legros et al. 1984).
Infusion rates up to 10 mIU/min reflect levels seen
during normal physiological labour. We assume that
oxytocin may be less tolerated in elderly and Covid-19
weakened patients and therefore low doses of oxyto-
cin should be given. Based on these considerations we
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suggest that oxytocin should be infused at low infu-
sion rates, gradually being increased from 1-10 mIU/
min for some hours, during monitoring of the cardio-
vascular function.
Treatment with intranasal oxytocin may be an
option in less sick individuals to prevent the develop-
ment of inflammation. The pharmacokinetics are not
as well described, and the administration is not as eas-
ily monitored as for intravenous infusion of oxytocin.
The direct beneficial effects of increasing circulating
oxytocin levels by i.v. infusion may be potentiated by
an enhancement of the endogenous oxytocin activity.
Enhanced levels of oxytocin in the circulation may, via
activation of afferent sensory nerves, stimulate oxyto-
cin release from nerves within the brain that emanate
from the hypothalamus (Velandia 2012). Afferent vagal
fibres may be involved in a reciprocal feed-back signal
of blood oxytocin to the brain (Iwasaki et al. 2015),
but other sensory nerves may also be involved
(Uvn€as-Moberg et al. 2014). This may lead to neural
release of oxytocin into several important regulatory
areas of the brain including the dorsal vagal complex
in the brainstem (Uvn€as-Moberg et al. 2014).
Subsequently, vagal tone may be increased promoting
the cholinergic anti-inflammatory pathway (Borovikova
et al. 2000). In addition, the neural release of oxytocin
into different parts of the brain may be associated
with an attenuation of stress, fear and pain (Uvn€as-
Moberg et al. 2014).
Conclusion
Oxytocin is a natural, safe and well-known drug with a
substantial anti-inflammatory and anti-stress potential.
In addition, in comparison with glucocorticoids, oxyto-
cin may promote rather than suppress the adaptive
immune response due to its putative stimulatory
effects on lymphocytes. Finally, the restorative proper-
ties of oxytocin may promote recovery and shorten
the time period of patient’s hospitalisation. Oxytocin is
readily available, as it is presently being used in most
hospitals. Infusion regimens, pharmacokinetic proper-
ties and safety are well established. In the present
situation with a worldwide progression of the Covid-
19 pandemic that challenges the entire global health
resources, it is urgent to identify inexpensive and safe
agents that can relieve the course of the disease. We
therefore propose that i.v. infusion of oxytocin should
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